{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T10:29:21Z","timestamp":1793096961938,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Colorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide. Development of novel chemotherapeutics is still required to enable successful treatment and improve survival for CRC patients. Here, we found that osimertinib (OSI) exhibits potent anti-CRC effects by inducing apoptosis, independent of its selective inhibitory activity targeting the EGFR T790M mutation. Intriguingly, OSI treatment triggers autophagic flux in CRC cells. Inhibition of autophagy markedly augments OSI-induced apoptosis and growth inhibition in CRC cells, suggesting a protective role of autophagy in response to OSI treatment. Mechanistically, OSI upregulates the expression of monocarboxylate transporter 1 (MCT1) and subsequently activates LKB1\/AMPK signaling, leading to autophagy induction in CRC cells. Notably, OSI significantly exaggerates the sensitivity of CRC cells to the first-line drugs 5-fluorouracil or oxaliplatin. Taken together, our study unravels a novel mechanism of OSI-mediated protective autophagy involving MCT1\/LKB1\/AMPK signaling, and suggests the use of OSI as a potential agent for clinical CRC treatment.<\/jats:p>","DOI":"10.1038\/s41419-019-1844-2","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T10:02:58Z","timestamp":1565690578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["MCT1 relieves osimertinib-induced CRC suppression by promoting autophagy through the LKB1\/AMPK signaling"],"prefix":"10.1038","volume":"10","author":[{"given":"Ping","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8325-2793","authenticated-orcid":false,"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyue","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard C.","family":"Nice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"1844_CR1","unstructured":"Key Statistics for Colorectal Cancer. https:\/\/www.cancer.org\/cancer\/colon-rectal-cancer\/about\/key-statistics.html (2019)."},{"key":"1844_CR2","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1200\/JCO.2008.20.9817","volume":"27","author":"GA Poultsides","year":"2009","unstructured":"Poultsides, G. A. et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J. Clin. Oncol. 27, 3379\u20133384 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1844_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W van Gijn","year":"2011","unstructured":"van Gijn, W. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 12, 575\u2013582 (2011).","journal-title":"Lancet Oncol."},{"key":"1844_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0128-8","volume":"50","author":"L He","year":"2018","unstructured":"He, L. et al. Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells. Exp. Mol. Med. 50, 101 (2018).","journal-title":"Exp. Mol. Med."},{"key":"1844_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cell.2014.02.049","volume":"157","author":"DR Green","year":"2014","unstructured":"Green, D. R. & Levine, B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell 157, 65\u201375 (2014).","journal-title":"Cell"},{"key":"1844_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-017-0436-9","volume":"10","author":"GJ Yoshida","year":"2017","unstructured":"Yoshida, G. J. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J. Hematol. Oncol. 10, 67\u201367 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"1844_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13046-018-0835-y","volume":"37","author":"GJ Yoshida","year":"2018","unstructured":"Yoshida, G. J. Emerging roles of Myc in stem cell biology and novel tumor therapies. J. Exp. Clin. Cancer Res. 37, 173\u2013173 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1844_CR8","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1093\/hmg\/ddt381","volume":"22","author":"PPC Toh","year":"2013","unstructured":"Toh, P. P. C. et al. Myc inhibition impairs autophagosome formation. Hum. Mol. Genet. 22, 5237\u20135248 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"1844_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nrm3461","volume":"13","author":"M Raices","year":"2012","unstructured":"Raices, M. & D\u2019Angelo, M. A. Nuclear pore complex composition: a new regulator of tissue-specific and developmental functions. Nat. Rev. Mol. Cell Biol. 13, 687 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1844_CR10","doi-asserted-by":"crossref","first-page":"62759","DOI":"10.18632\/oncotarget.18663","volume":"8","author":"H-R Qian","year":"2017","unstructured":"Qian, H.-R. et al. Interplay between apoptosis and autophagy in colorectal cancer. Oncotarget 8, 62759\u201362768 (2017).","journal-title":"Oncotarget"},{"key":"1844_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.phymed.2015.08.009","volume":"22","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Dihydrotanshinone I induced apoptosis and autophagy through caspase dependent pathway in colon cancer. Phytomedicine 22, 1079\u20131087 (2015).","journal-title":"Phytomedicine"},{"key":"1844_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","volume":"34","author":"GJ Yoshida","year":"2015","unstructured":"Yoshida, G. J. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J. Exp. Clin. Cancer Res. 34, 111 (2015).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1844_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.gastro.2004.12.003","volume":"128","author":"M Cuff","year":"2005","unstructured":"Cuff, M., Dyer, J., Jones, M. & Shirazi-Beechey, S. The human colonic monocarboxylate transporter Isoform 1: its potential importance to colonic tissue homeostasis. Gastroenterology 128, 676\u2013686 (2005).","journal-title":"Gastroenterology"},{"key":"1844_CR14","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.ejca.2009.06.018","volume":"45","author":"C Pinheiro","year":"2009","unstructured":"Pinheiro, C. et al. The prognostic value of CD147\/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur. J. Cancer 45, 2418\u20132424 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1844_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.canlet.2015.05.015","volume":"365","author":"R Amorim","year":"2015","unstructured":"Amorim, R. et al. Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. Cancer Lett. 365, 68\u201378 (2015).","journal-title":"Cancer Lett."},{"key":"1844_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13046-018-0673-y","volume":"37","author":"Q Fan","year":"2018","unstructured":"Fan, Q. et al. Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt\/beta-catenin signaling pathway activation in hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. 37, 9 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1844_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ccell.2015.05.012","volume":"27","author":"K Politi","year":"2015","unstructured":"Politi, K., Ayeni, D. & Lynch, T. The next wave of EGFR tyrosine kinase inhibitors enter the clinic. Cancer Cell 27, 751\u2013753 (2015).","journal-title":"Cancer Cell"},{"key":"1844_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/15548627.2017.1409405","volume":"14","author":"K Wang","year":"2018","unstructured":"Wang, K. et al. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux. Autophagy 14, 269\u2013282 (2018).","journal-title":"Autophagy"},{"key":"1844_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0065-2423(10)51004-7","volume":"51","author":"B Markman","year":"2010","unstructured":"Markman, B., Javier Ramos, F., Capdevila, J. & Tabernero, J. EGFR and KRAS in colorectal cancer. Adv. Clin. Chem. 51, 71\u2013119 (2010).","journal-title":"Adv. Clin. Chem."},{"key":"1844_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3322\/canjclin.55.3.178","volume":"55","author":"IM Ghobrial","year":"2005","unstructured":"Ghobrial, I. M., Witzig, T. E. & Adjei, A. A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178\u2013194 (2005).","journal-title":"CA Cancer J. Clin."},{"key":"1844_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrd.2016.23","volume":"15","author":"A Mullard","year":"2016","unstructured":"Mullard, A. Pioneering apoptosis-targeted cancer drug poised for FDA approval. Nat. Rev. Drug Discov. 15, 147\u2013149 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1844_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.350","volume":"4","author":"X Sui","year":"2013","unstructured":"Sui, X. et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 4, e838 (2013).","journal-title":"Cell Death Dis."},{"key":"1844_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"DJ Klionsky","year":"2016","unstructured":"Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1\u2013222 (2016).","journal-title":"Autophagy"},{"key":"1844_CR24","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.31335","volume":"124","author":"AV Onorati","year":"2018","unstructured":"Onorati, A. V., Dyczynski, M., Ojha, R. & Amaravadi, R. K. Targeting autophagy in cancer. Cancer 124, 3307\u20133318 (2018).","journal-title":"Cancer"},{"key":"1844_CR25","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.4161\/auto.7.11.16664","volume":"7","author":"CE Zois","year":"2011","unstructured":"Zois, C. E. et al. \u201cAutophagic flux\u201d in normal mouse tissues: focus on endogenous LC3A processing. Autophagy 7, 1371\u20131378 (2011).","journal-title":"Autophagy"},{"issue":"6","key":"1844_CR26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1089\/ars.2018.7649","volume":"31","author":"Se-Jin Jeong","year":"2019","unstructured":"Jeong, S.-J., Zhang, X., Rodriguez-Velez, A., Evans, T. D. & Razani, B. p62\/SQSTM1 and Selective Autophagy in Cardiometabolic Diseases. Antioxid. Redox. Signal. https:\/\/doi.org\/10.1089\/ars.2018.7649 (2018).","journal-title":"Antioxidants & Redox Signaling"},{"key":"1844_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.7150\/thno.20356","volume":"8","author":"J Zeng","year":"2018","unstructured":"Zeng, J., Liu, W., Fan, Y. Z., He, D. L. & Li, L. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1\/AMPK-mediated autophagy. Theranostics 8, 109\u2013123 (2018).","journal-title":"Theranostics"},{"key":"1844_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/annurev-arplant-043014-114648","volume":"67","author":"T Dobrenel","year":"2016","unstructured":"Dobrenel, T. et al. TOR signaling and nutrient sensing. Annu. Rev. Plant Biol. 67, 261\u2013285 (2016).","journal-title":"Annu. Rev. Plant Biol."},{"key":"1844_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cell.2012.12.016","volume":"152","author":"J Kim","year":"2013","unstructured":"Kim, J. et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell 152, 290\u2013303 (2013).","journal-title":"Cell"},{"key":"1844_CR30","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1002\/mc.22707","volume":"56","author":"V Miranda-Goncalves","year":"2017","unstructured":"Miranda-Goncalves, V. et al. Monocarboxylate transporter 1 is a key player in glioma-endothelial cell crosstalk. Mol. Carcinog. 56, 2630\u20132642 (2017).","journal-title":"Mol. Carcinog."},{"key":"1844_CR31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/jcb.27434","volume":"120","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z., Zhang, M., Liu, H. & Yin, W. AZD9291 promotes autophagy and inhibits PI3K\/Akt pathway in NSCLC cancer cells. J. Cell Biochem. 120, 756\u2013767 (2019).","journal-title":"J. Cell Biochem."},{"key":"1844_CR32","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1053\/j.gastro.2004.10.001","volume":"127","author":"A Tajima","year":"2004","unstructured":"Tajima, A., Hess, M. T., Cabrera, B. L., Kolodner, R. D. & Carethers, J. M. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 127, 1678\u20131684 (2004).","journal-title":"Gastroenterology"},{"key":"1844_CR33","doi-asserted-by":"publisher","first-page":"djt322","DOI":"10.1093\/jnci\/djt322","volume":"106","author":"C Moutinho","year":"2014","unstructured":"Moutinho, C. et al. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. J. Natl. Cancer Inst. 106, djt322 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"1844_CR34","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1667\/RR14682.1","volume":"189","author":"S Wu","year":"2018","unstructured":"Wu, S. et al. AZD9291 increases sensitivity to radiation in PC-9-IR cells by delaying DNA damage repair after irradiation and inducing apoptosis. Radiat. Res. 189, 283\u2013291 (2018).","journal-title":"Radiat. Res."},{"key":"1844_CR35","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.2147\/OTT.S139382","volume":"10","author":"L Guo","year":"2017","unstructured":"Guo, L., Huang, S. & Wang, X. PUMA mediates the anti-cancer effect of osimertinib in colon cancer cells. Onco Targets Ther. 10, 5281\u20135288 (2017).","journal-title":"Onco Targets Ther."},{"key":"1844_CR36","doi-asserted-by":"crossref","unstructured":"AACR publication group. AZD9291 could be an option for NSCLC. Cancer Discov. 4, Of10 (2014).","DOI":"10.1158\/2159-8290.CD-NB2014-077"},{"key":"1844_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross, D. A. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046\u20131061 (2014).","journal-title":"Cancer Discov."},{"key":"1844_CR38","doi-asserted-by":"publisher","first-page":"38789","DOI":"10.18632\/oncotarget.5887","volume":"6","author":"T Hirano","year":"2015","unstructured":"Hirano, T. et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget 6, 38789\u201338803 (2015).","journal-title":"Oncotarget"},{"key":"1844_CR39","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1158\/0008-5472.CAN-12-3765","volume":"73","author":"L Kohli","year":"2013","unstructured":"Kohli, L. et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res. 73, 4395\u20134405 (2013).","journal-title":"Cancer Res."},{"key":"1844_CR40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3389\/fonc.2018.00599","volume":"8","author":"M Yeon","year":"2018","unstructured":"Yeon, M. et al. CAGE binds to Beclin1, regulates autophagic flux and CAGE-derived peptide confers sensitivity to anti-cancer drugs in non-small cell lung cancer cells. Front. Oncol. 8, 599\u2013599 (2018).","journal-title":"Front. Oncol."},{"key":"1844_CR41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.canlet.2018.02.004","volume":"420","author":"ZH Tang","year":"2018","unstructured":"Tang, Z. H. & Lu, J. J. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Lett. 420, 242\u2013246 (2018).","journal-title":"Cancer Lett."},{"key":"1844_CR42","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","volume":"26","author":"D Planchard","year":"2015","unstructured":"Planchard, D. et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann. Oncol. 26, 2073\u20132078 (2015).","journal-title":"Ann. Oncol."},{"key":"1844_CR43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2174\/1871520617666170719155517","volume":"18","author":"ZH Tang","year":"2018","unstructured":"Tang, Z. H. et al. Increased expression of IRE1alpha associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827\/OSIR cells. Anticancer Agents Med. Chem. 18, 550\u2013555 (2018).","journal-title":"Anticancer Agents Med. Chem."},{"key":"1844_CR44","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","volume":"75","author":"CA Eberlein","year":"2015","unstructured":"Eberlein, C. A. et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 75, 2489\u20132500 (2015).","journal-title":"Cancer Res."},{"key":"1844_CR45","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1038\/s41467-018-07132-x","volume":"9","author":"Q Yang","year":"2018","unstructured":"Yang, Q. et al. PRKAA1\/AMPK\u03b11-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis. Nat. Commun. 9, 4667\u20134667 (2018).","journal-title":"Nat. Commun."},{"key":"1844_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","volume":"10","author":"J Rodon","year":"2013","unstructured":"Rodon, J., Dienstmann, R., Serra, V. & Tabernero, J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10, 143 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1844_CR47","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1080\/15548627.2017.1332565","volume":"13","author":"SJ Chung","year":"2017","unstructured":"Chung, S. J. et al. ADIPOQ\/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11\/LKB1-mediated activation of the AMPK-ULK1 axis. Autophagy 13, 1386\u20131403 (2017).","journal-title":"Autophagy"},{"key":"1844_CR48","first-page":"3835","volume":"118","author":"GL Semenza","year":"2008","unstructured":"Semenza, G. L. Tumor metabolism: cancer cells give and take lactate. J. Clin. Invest. 118, 3835\u20133837 (2008).","journal-title":"J. Clin. Invest."},{"key":"1844_CR49","first-page":"3930","volume":"118","author":"P Sonveaux","year":"2008","unstructured":"Sonveaux, P. et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. T J. Clin. Invest. 118, 3930\u20133942 (2008).","journal-title":"T J. Clin. Invest."},{"key":"1844_CR50","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s12885-016-2566-9","volume":"16","author":"SF Martins","year":"2016","unstructured":"Martins, S. F. et al. Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis. BMC Cancer 16, 535\u2013535 (2016).","journal-title":"BMC Cancer"},{"key":"1844_CR51","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/1078-0432.CCR-13-2270","volume":"20","author":"R Pola\u0144ski","year":"2014","unstructured":"Pola\u0144ski, R. et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin. Cancer Res. 20, 926\u2013937 (2014).","journal-title":"Clin. Cancer Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1844-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1844-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1844-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:28:22Z","timestamp":1671211702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1844-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["1844"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1844-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"10 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"615"}}